Pancreatic Resection in Fit Octogenarians With Nonmetastatic Pancreatic Cancer
PRONPaC
1 other identifier
observational
2,048
1 country
1
Brief Summary
This study looks at how different treatment approaches affect survival in older people with pancreatic cancer that has not spread to other parts of the body. In particular, it focuses on patients aged 80 years and older who are still in relatively good general health and able to carry out normal daily activities. Pancreatic cancer is a serious disease, and surgery to remove the tumor is often the only treatment that offers a chance of longer survival. However, older patients are less likely to receive surgery, even if they are otherwise fit. Doctors may hesitate to recommend surgery mainly because of the patient's age, rather than their overall health condition. This study aims to better understand whether surgery can still be beneficial for these older patients. The study also examines the role of additional treatment after surgery, such as chemotherapy. In real-world medical practice, not all patients receive this follow-up treatment, especially older individuals who may have a slower recovery after surgery. This can make it difficult to understand whether such treatments truly improve survival. To answer these questions, the study uses data from a large cancer registry in Germany. It compares patients who had surgery with those who did not, and it also looks at patients who received additional treatment after surgery versus those who did not. Special methods are used to take into account that some patients may not have been able to receive further treatment because they did not recover well enough after surgery. The results of this study are intended to help doctors make better treatment decisions for older patients with pancreatic cancer, focusing more on their overall health and less on age alone.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2017
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
October 12, 2024
CompletedFirst Submitted
Initial submission to the registry
April 15, 2026
CompletedFirst Posted
Study publicly available on registry
April 21, 2026
CompletedApril 21, 2026
April 1, 2026
7 years
April 15, 2026
April 15, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Overall Survival
1 year overall survival after index surgery
Study Arms (2)
Patients younger than 80 years
Patients between 80 and 89 years
Interventions
Eligibility Criteria
All residents of the Federal States Brandenburg and Berlin
You may qualify if:
- Diagnosis of invasive pancreatic carcinoma
- UICC stage I-III
- No distant metastases (M0)
- ECOG performance status 0-1
- Diagnosis between Jan 1, 2017 and Dec 31, 2023
- Residence in Berlin or Brandenburg
You may not qualify if:
- Neuroendocrine tumors
- Sarcomas
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Medical School Brandenburg
Brandenburg an der Havel, Brandenburg, 14770, Germany
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal investigator
Study Record Dates
First Submitted
April 15, 2026
First Posted
April 21, 2026
Study Start
January 1, 2017
Primary Completion
December 31, 2023
Study Completion
October 12, 2024
Last Updated
April 21, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will not share
Individual participant data (IPD) cannot be shared. The data used in this study were obtained from a regional clinical cancer registry and are subject to strict data protection regulations. The dataset contains sensitive, potentially identifiable health information and is governed by legal restrictions that prohibit public data sharing.